

Daphne R Friedman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3802764/publications.pdf>

Version: 2024-02-01

29
papers

383
citations

840776

11
h-index

794594

19
g-index

30
all docs

30
docs citations

30
times ranked

859
citing authors

#	ARTICLE	IF	CITATIONS
1	SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. <i>Blood</i> , 2011, 118, 4150-4158.	1.4	108
2	Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2007, 82, 1063-1070.	4.1	47
3	A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2009, 15, 6947-6955.	7.0	37
4	Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and <i>in vitro</i> studies. <i>Leukemia and Lymphoma</i> , 2014, 55, 1067-1075.	1.3	28
5	<i>SET</i> alpha and <i>SET</i> beta mRNA isoforms in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 605-615.	2.5	24
6	Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. <i>American Journal of Hematology</i> , 2016, 91, 687-691.	4.1	20
7	Utilization of the <i>1/4-Myc</i> Mouse to Model Heterogeneity of Therapeutic Response. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3219-3229.	4.1	19
8	Statin use and need for therapy in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 2295-2298.	1.3	18
9	Perifosine as a potential novel anti-telomerase therapy. <i>Oncotarget</i> , 2015, 6, 21816-21826.	1.8	18
10	Informational needs assessment of non-Hodgkin lymphoma survivors and their physicians. <i>American Journal of Hematology</i> , 2010, 85, 528-532.	4.1	17
11	CD38 variation as a prognostic factor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 191-194.	1.3	11
12	Influence of Statin Therapy On the Clinical Course of Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 2344-2344.	1.4	9
13	Lipids and Their Effects in Chronic Lymphocytic Leukemia. <i>EBioMedicine</i> , 2017, 15, 2-3.	6.1	6
14	Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling. <i>British Journal of Haematology</i> , 2018, 183, 747-754.	2.5	5
15	Comparison of the PI3K- γ Inhibitors TGR1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells <i>In Vitro</i> . <i>Blood</i> , 2012, 120, 3914-3914.	1.4	5
16	Clinical and Biological Relevance of Genomic Heterogeneity in Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2013, 8, e57356.	2.5	4
17	Integration of Patient-Reported Outcome Measures in the Electronic Health Record: The Veterans Affairs Experience. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100086.	2.1	3
18	Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 1842-1842.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Modeling Variation in the Human Lymphoma Microenvironment with the E $\frac{1}{4}$ -Myc Mouse Model. <i>Blood</i> , 2012, 120, 789-789.	1.4	1
20	“Primum non nocere” the addition of granulocyte-macrophage colony stimulating factor to alemtuzumab in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 441-442.	1.3	0
21	Post-translational regulation could be determine functional differences between α and β isoform “ Response to Crist ³ bal <i>et al</i> . <i>British Journal of Haematology</i> , 2019, 186, 637-637.	2.5	0
22	Identification of Therapeutic Targets for Chronic Lymphocytic Leukemia in the Relapsed and Refractory Setting.. <i>Blood</i> , 2008, 112, 2068-2068.	1.4	0
23	The Anti-Inflammatory Investigational Agent LMP-420 Demonstrates in Vitro Cytotoxic Activity against Chronic Lymphocytic Leukemia Cells.. <i>Blood</i> , 2009, 114, 2358-2358.	1.4	0
24	A Comprehensive Identification of the MicroRNA Transcriptome and Its Application in B Cell Malignancies.. <i>Blood</i> , 2009, 114, 2403-2403.	1.4	0
25	Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells. <i>Blood</i> , 2011, 118, 286-286.	1.4	0
26	Genomic Heterogeneity in B-Cell Malignancies,. <i>Blood</i> , 2011, 118, 3465-3465.	1.4	0
27	CD38 Variation in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 4576-4576.	1.4	0
28	Partners in Oncology Care: Coordinated Follicular Lymphoma Management. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019, 36, S21-S23.	0.6	0
29	Identifying and Overcoming Barriers in Clinical Trial Enrollment for Veterans with Blood Cancers. <i>Blood</i> , 2021, 138, 1920-1920.	1.4	0